SEC Form 4 · accession 0001209191-17-036623
Forte Biosciences, Inc. · FBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Asha Das
Officer — SVP & Chief Medical Officer
Period of report
May 26, 2017
Accepted (ET)
May 31, 2017 · 9:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419041
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $16.32 | May 26, 2017 | A | 130,000 | A | — | May 25, 2027 | Common Stock | 130,000 | 130,000 | D |
Explanation of responses
- F11/4th of the shares vest one year after 5/26/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 5/26/2017.